The tablet waits for nitric oxide, not the other way around

No nitric oxide, no useful flow on a PDE5 card

No nitric oxide, no useful flow on a PDE5 card. The enzyme block only matters after sexual stimulation starts NO release in the corpora. Without that first signal, cGMP stays low. The tablet waits. It does not invent desire, and it does not open helicine arteries on a timer.

Men treat the card like a light switch. Then they report failure after a silent hour. This stack files that as a counseling miss, not as a weak ANDA. Raise the dose and you still need the same NO. The ceiling moves milligrams. It does not move the pathway.

The three cards on this library - sildenafil, tadalafil, vardenafil - share that rule. Daily tadalafil keeps some inhibition in the background. Zero stimulation still yields zero useful rigidity. Plan arousal with the swallow. The card does not start the evening.

Nitrates stay a hard stop on every card

Nitrates stay a hard stop on every card. Brand stamp, AB generic, daily tadalafil, PRN sildenafil - the stop does not slide. Organic nitrates plus PDE5 raise cGMP from both ends. Blood pressure falls. That is a class rule, not a logo rule.

Riociguat is the same kind of stop. Ask about chest-pain spray, isosorbide, and poppers before you talk about which card in the stack fits the weekend. The ANDA card versus informal blister article does not loosen this line. Neither does a cheaper NDC.

Introduction: ED as Hemodynamic Failure, Not a Missing Switch

ED is hemodynamic failure during arousal - not missing libido in a bottle.

Patients imagine desire alone controls rigidity. erection is arterial inflow plus veno-occlusive trapping in expanding sinusoids - a pressure state that fails when endothelium, nerves, or tunica mechanics break down.

Oral phosphodiesterase type 5 (PDE5) inhibitors became first-line pharmacotherapy after sildenafil's 1998 approval because they target a specific enzymatic step in a validated pathway rather than injecting vasodilators directly into the corpora. They work in a substantial fraction of men with mild-to-moderate vasculogenic ED and fail predictably when nitric oxide delivery or veno-occlusive mechanics are severely compromised.

Card note: successful prescribing requires you to explain what the pill does and what it cannot do. It amplifies a signal that sexual stimulation must initiate. It does not increase libido in isolation, does not reverse severe cavernous nerve transection overnight, and does not replace treatment of glucose, blood pressure, or lipid disorders driving endothelial disease.

Card note: assessment before first prescription includes cardiovascular risk stratification because sexual activity increases myocardial oxygen demand comparable to moderate exercise. Unstable angina, decompensated heart failure, and uncontrolled arrhythmias contraindicate sexual activity-and thus PDE5 use-until stabilized.

This article focuses on pharmacology linking pathophysiology to the three PDE5 inhibitors detailed on this site: sildenafil, tadalafil, and vardenafil. Second-line intracavernosal alprostadil, vacuum devices, and penile prosthesis sit outside today's scope but remain essential when oral PDE5 therapy fails after optimized trials.

Women partners and same-sex couples raise legitimate questions about indirect benefit; PDE5 inhibitors have no approved female indication and do not treat hypoactive desire in men-that is a separate diagnostic pathway. Keep the mechanism story precise to avoid overpromising.

Telehealth prescribing accelerated ED treatment access; it also skipped cardiovascular histories in some platforms. The pharmacology and contraindications here apply whether the script originated in an office or on a phone screen.

Priapism lasting beyond four hours is a urologic emergency for any PDE5 inhibitor-generic or brand. Patient leaflets must include this regardless of manufacturer.

Pediatric and adolescent use of sildenafil for pulmonary hypertension indications uses different strengths than ED tablets; family medication reconciliation prevents pediatric Revatio dosing errors when adult ED generics also sit in the home.

Structured history for ED duration, morning erections, libido, partner factors, and medication list takes minutes and prevents misprescribing PDE5 inhibitors when testosterone or depression treatment is the actual need.

The Princeton Consensus framework asks whether cardiac disease is stable enough for sexual activity before asking which PDE5 agent to choose-exercise tolerance and nitrate use screening belong in the same visit as the first prescription.

Definition, Epidemiology, and Etiologic Categories

The NIH Consensus Conference defined ED as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. Epidemiologic surveys using IIEF questionnaires put moderate-to-complete ED around 15-25% of men aged 40-70, higher in diabetes and post-myocardial infarction cohorts.

Duration and pattern distinguish organic from psychogenic contributions. Sudden onset with situational preservation, intact morning erections, and high libido suggest psychogenic or performance-anxiety components. Gradual worsening with comorbid vascular disease points organic. Mixed etiology is common; fixing the blood pressure does not automatically erase anxiety learned after repeated failures.

The Massachusetts Male Aging Study and successors established ED as a chronic medical condition rather than a cosmetic complaint. Longitudinal data link baseline ED severity with later cardiovascular events, framing the history as vascular triage-not just a prescription pad moment.

Card note: validated tools include the IIEF-5 (SHIM) and full IIEF domains, plus Erection Hardness Score in trials. A drop of four points on the erectile function domain often defines clinically meaningful improvement in registration studies; office follow-up can reuse the same instruments.

Organic categories include vasculogenic (endothelial and arterial insufficiency, venous leak), neurogenic (spinal cord injury, radical prostatectomy), hormonal (hypogonadism reducing libido and NO synthase expression), and drug-induced (SSRIs, thiazides, antiandrogens). Medication review belongs before dose escalation.

Psychogenic and relational factors alter sympathetic outflow during attempted intercourse; PDE5 inhibitors plus brief counseling outperform either alone in mixed cases. Partner distress scales are underused but informative.

Classification guides expectations: post-prostatectomy ED with non-nerve-sparing surgery responds less to PDE5 monotherapy than mild vasculogenic ED in a newly diagnosed hypertensive patient whose endothelial function improves with ACE inhibition and weight loss.

Age alone is not etiology. An 80-year-old with new ED and claudication needs vascular workup, not automatic dismissal as normal aging. Conversely, a 28-year-old with situational failure and normal examination may need counseling more than maximum-dose sildenafil.

IIEF-5 scores of 21 or below define ED in many epidemiologic cutoffs; borderline scores benefit from repeat assessment with partner input. Depression screens (PHQ-9) belong in mixed presentations because treating mood sometimes restores function without PDE5 exposure.

Shift work and sleep deprivation impair libido and erectile quality through central mechanisms; fixing sleep hygiene may complement pharmacotherapy in occupational cohorts without additional pill burden.

Chronic kidney disease and dialysis alter protein binding and clearance for PDE5 agents differently by molecule-dose adjustment tables in monographs supersede generic class assumptions.

Spinal cord injury with preserved sacral reflexes may retain reflexogenic erections; PDE5 inhibitors can augment perfusion when partner stimulation triggers local NO despite absent psychogenic erections in complete lesions.

The Nitric Oxide-cGMP Pathway in Corpus Cavernosum

Penile tumescence depends on parasympathetic and nonadrenergic noncholinergic (NANC) activity during sexual stimulation, releasing nitric oxide near cavernous nerve terminals and endothelial surfaces.

Nitric oxide diffuses into trabecular and arterial smooth muscle cells, activating soluble guanylate cyclase (sGC). sGC converts GTP to cyclic guanosine monophosphate (cGMP). Elevated cGMP activates protein kinase G (PKG), which lowers intracellular calcium through sequestration and membrane hyperpolarization, producing smooth muscle relaxation.

Relaxation of cavernosal sinusoids and helicine arteries increases arterial inflow-up to roughly 100 mL/min at full rigidity. Expansion of sinusoids against the tunica albuginea compresses subtunical venules, reducing venous outflow. That veno-occlusive mechanism converts increased inflow into sustained rigidity; failure at any step yields clinically apparent ED.

Card note: detumescence restores sympathetic tone, hydrolyzes cGMP via phosphodiesterases-predominantly PDE5 in corpus cavernosum-and contracts smooth muscle. PDE5 is enriched in penile tissue relative to many other vascular beds, providing a selective pharmacologic target.

Endothelial dysfunction from diabetes, hypertension, smoking, and hyperlipidemia reduces NO bioavailability before structural cavernosal fibrosis develops. You can have a patient who "passes" a morning testosterone but still shows attenuated NO-mediated dilation-PDE5 inhibitors raise cGMP only if some NO is present.

Cavernous nerve injury from pelvic surgery disrupts neural NO delivery; smooth muscle and endothelium may still respond if perfusion is restored pharmacologically during rehabilitation windows. Venous leak syndromes from tunica or trabecular disease limit occlusion despite reasonable inflow-PDE5 inhibitors help less.

Testosterone modulates libido and supports NO synthase expression in hypogonadal men; biochemical hypogonadism with symptoms may need androgen replacement alongside PDE5 therapy for full benefit. Low desire with preserved nocturnal erections suggests primary libido or relational issues rather than pure vasculogenic failure.

Ischiocavernosus and bulbospongiosus muscles augment rigidity after veno-occlusion; pure smooth muscle relaxation without muscular compression may yield softer erections in some men. Pelvic floor physical therapy occasionally complements pharmacotherapy in post-procedural rehabilitation.

Soluble guanylate cyclase stimulators (riociguat) raise cGMP through a parallel pathway; combining them with PDE5 inhibitors is contraindicated because degradation is blocked while synthesis is stimulated-a pharmacology lesson that generalizes beyond ED.

Fibrosis of trabecular smooth muscle in long-standing diabetes or after priapism reduces compliance of sinusoids; PDE5 inhibitors cannot reverse structural cavernosal damage, only enhance signaling in remaining functional tissue.

Card note: pelvic radiation for prostate or rectal malignancy damages microvasculature and nerves with latency before ED presents-PDE5 trials should start with realistic expectations and concurrent vascular risk management.

Bicycle saddle compression neuropathy contributes rarely to vascular-type ED in high-mileage cyclists; history matters before attributing failure purely to PDE5 dose.

Corpus cavernosum oxygen tension rises during erection; chronic ischemia from untreated ED may contribute to smooth muscle fibrosis over years-early PDE5 use in motivated patients may have structural preservation rationale beyond symptomatic intercourse.

Why Sexual Stimulation Is Required for PDE5 Inhibitors to Work

PDE5 inhibitors are enzymatic brakes on cGMP breakdown, not ignition switches for erection. Without arousal-driven nitric oxide release, cGMP levels remain low and blocking PDE5 changes little.

This is the sentence patients must hear: the pill does not create an erection-it keeps cGMP around longer when you are already being stimulated. Spontaneous erections during unrelated daily activity are not the intended effect and occur rarely at therapeutic doses.

Central arousal activates parasympathetic outflow and local NANC neurotransmission. Visual, tactile, and cognitive inputs integrate in spinal and supraspinal circuits. Performance anxiety increases sympathetic tone, opposing relaxation even when a PDE5 inhibitor is on board-explaining partial failures in psychogenic-mixed cases despite adequate dosing.

Registration trials standardized sexual attempts and partner context; real-world success depends on timing relative to dose, food (for sildenafil and vardenafil), alcohol intake, fatigue, and relationship dynamics. A man who takes sildenafil after a heavy steak, drinks heavily, and attempts intercourse without foreplay may conclude the drug class failed when pharmacokinetics and arousal both worked against him.

Contrast with intracavernosal alprostadil, a prostaglandin that directly relaxes smooth muscle independent of NO. That mechanistic difference explains why injection therapy succeeds in some post-procedural patients who report zero response to oral PDE5 drugs-not because oral agents are "weak," but because the pathway bypass differs.

Daily low-dose tadalafil maintains some PDE5 inhibition continuously, lowering the threshold for stimulation-triggered responses in men who prefer frequent activity or combined BPH-LUTS indication. Even then, zero stimulation produces zero meaningful erection.

Counseling language that works: "Plan arousal and timing together with the dose; the tablet waits for your nervous system to start the signal."

Nocturnal penile tumescence during REM sleep occurs with intact spinal reflex arcs even when psychogenic ED dominates waking attempts-finding preserved NPT on sleep study or stamp test history supports neurologic capacity for erection when adequate stimulation returns.

SSRIs blunt libido and delay orgasm through central mechanisms independent of PDE5; switching antidepressants or adding bupropion may help more than escalating vardenafil dose in SSRI-associated ED.

Partners who initiate without allowing time for tablet absorption and foreplay set up failure cycles. Brief joint counseling on realistic timelines after sildenafil or vardenafil dosing prevents blaming the molecule for scheduling errors.

Card note: watching pornography immediately before intercourse does not substitute for partner-focused arousal in men with relational ED; PDE5 inhibitors still require psychogenic activation of parasympathetic outflow. Referral for sex therapy remains appropriate when arousal cannot be sustained despite adequate corporal pharmacology.

PDE5 Inhibition: Class Pharmacology Shared by Sildenafil, Tadalafil, and Vardenafil

All three agents on this site selectively inhibit PDE5, prolonging cGMP action in corpus cavernosum and pulmonary vasculature (sildenafil and tadalafil also carry PAH indications at different doses).

Biochemical selectivity varies: sildenafil shows weaker selectivity over PDE6 (retinal), explaining blue-tinted vision at higher doses; tadalafil has long half-life and some PDE11 activity speculated to relate to back pain; vardenafil is structurally related to sildenafil with similar food sensitivity. These differences inform adverse effect profiles more than categorical efficacy superiority in meta-analyses at equipotent exposures.

Onset for PRN use: sildenafil and vardenafil peak around 60 minutes fasted, with functional windows roughly four to five hours. Tadalafil peaks later but persists up to 36 hours in labeling language, supporting PRN 10-20 mg or daily 2.5-5 mg regimens with distinct indications.

Metabolism runs primarily through CYP3A4; strong inhibitors raise exposure and mandate dose caps per labeling. N-desmethylsildenafil is an active metabolite contributing to sildenafil's effect; vardenafil has an active metabolite as well. Tadalafil's long half-life means interaction consequences persist longer.

Common adverse effects reflect systemic vasodilation: headache, flushing, dyspepsia, nasal congestion. Visual and hearing disturbances remain class warnings across labels. Orthostatic symptoms matter in elderly men on multiple antihypertensives.

No tachyphylaxis from PDE5 downregulation is documented in long-term extensions; loss of effect over years usually tracks worsening vascular disease, progressive neuropathy, or partner and mood changes-not receptor adaptation.

Pivotal trials shared IIEF erectile function domain and diary-based successful intercourse endpoints. Response rates exceed 70% for successful attempts at optimized doses in general populations but fall in diabetes (~50-60%) and early post-prostatectomy (~25-40%) subgroups-set expectations accordingly.

Placebo arms in blinded trials improved IIEF scores through regression, psychogenic components, and repeated attempts-real-world response requires adequate dose trials, not single-tablet tests after years of untreated ED.

Crossover studies after blinded periods show patient preference splits among class members when equipotent doses compared-confirming meta-analytic findings that agent selection is tolerability and convenience, not categorical superiority.

Card note: hepatic CYP3A4 impairment and strong inhibitors disproportionately raise sildenafil and vardenafil exposure; tadalafil's long half-life prolongs interaction consequences. Renal impairment dose adjustments differ by label-verify monograph tables before copying one agent's rule to another.

Card note: pDE6 cross-reactivity produces visual hue changes at higher sildenafil doses; vardenafil shares some retinal PDE affinity; tadalafil back pain may relate to PDE11 but remains class-manageable by dose reduction or agent switch.

Pulmonary arterial hypertension dosing of sildenafil and tadalafil uses lower milligram amounts and different schedules than ED regimens-never interchange Revatio or Adcirca logic with ED tablets without specialist oversight.

Nitrates, Riociguat, and Hemodynamic Contraindications

Combined nitrate plus PDE5 inhibition is a pharmacodynamic catastrophe-class-wide, dose-independent at the level of mechanism, and unaffected by whether the tablet is generic or brand.

Card note: organic nitrates (nitroglycerin SL, isosorbide mononitrate, isosorbide dinitrate) increase cGMP via nitric oxide signaling. PDE5 inhibitors block degradation. The result is profound vasodilation, syncope, myocardial ischemia, and fatalities reported since class launch.

Riociguat, a soluble guanylate cyclase stimulator approved for pulmonary hypertension, is contraindicated with PDE5 inhibitors because cGMP rises through both synthesis and reduced breakdown. Never co-prescribe.

Amyl nitrite and butyl nitrite recreational inhalants count. Ask explicitly in social history.

Card note: alpha-1 blockers for BPH or hypertension require caution: labeling recommends stable tamsulosin dosing before PDE5 initiation and orthostatic monitoring. Absolute prohibition applies to nitrates, not all antihypertensives.

Card note: emergency nitrate use in patients who recently ingested a PDE5 inhibitor is a known crisis scenario. Washout intervals depend on half-life-shorter for sildenafil and vardenafil, longer for tadalafil. Document last dose in chest pain presentations.

Screen at every visit, not just initiation. Cardiology may add isosorbide without urology notified. Pharmacists catching the pair at dispensing prevent disasters.

Chest pain during intercourse in a man on tadalafil requires emergency evaluation for acute coronary syndrome-not reassurance that long half-life precludes nitrate use if ischemia is present. Avoid nitrates until PDE5 washout per emergency protocol and cardiology input.

Card note: recreational poppers (amyl nitrite) remain a contraindication in substance-using populations; ask in nonjudgmental substance history.

Guanylate cyclase stimulator labels for riociguat carry boxed warnings against PDE5 co-use; pulmonary hypertension patients may carry both prescriptions from different specialists unless systems communicate.

Card note: sildenafil and tadalafil pulmonary hypertension regimens use milligram doses and intervals incompatible with ED tablets-medication reconciliation at every visit prevents double therapy from duplicate generic and specialty pharmacy shipments.

Comorbid Vascular Disease: Treat the Arteries, Then the Penis

ED often precedes coronary events by years because penile arteries are smaller than coronaries. Optimizing vascular risk factors improves endothelial NO availability and PDE5 inhibitor response.

Control glycated hemoglobin, blood pressure, and lipids per guideline targets. Smoking cessation improves endothelial function measurably within months. Weight loss of ten percent body weight improves erectile function in obese men independent of PDE5 initiation in trial data.

Stable coronary artery disease does not automatically forbid PDE5 use. Princeton Consensus frameworks stratify exercise capacity: men who achieve moderate exertion without angina may use PDE5 inhibitors with modest blood pressure monitoring. Unstable or recent MI requires cardiology clearance.

Diabetes combines microvascular endothelial dysfunction and neuropathy; start at effective doses, consider daily tadalafil if frequent activity, and expect lower success rates than in nondiabetic cohorts. Retinopathy is not a contraindication, but PDE6-related visual symptoms warrant attention.

Hypertensive patients on multidrug regimens need interaction review. Thiazides and beta-blockers themselves worsen ED; switching antihypertensive class may help libido and hemodynamics more than escalating PDE5 dose.

Post-prostatectomy penile rehabilitation protocols often include early PDE5 use to support corporeal oxygenation during nerve recovery; nerve-sparing technique quality predicts pharmacologic success. Pelvic radiation causes delayed vasculopathy and neuropathy with attenuated response.

Sleep apnea treatment with CPAP may improve ED through multifactorial pathways. Hypogonadism screening belongs when libido is disproportionately low relative to erectile capacity.

Framing ED as a vascular signal helps men accept statins and ACE inhibitors-not just a sex pill visit.

Metabolic syndrome components cluster: insulin resistance, waist circumference, triglycerides, and blood pressure each independently worsen endothelial function. Treating the cluster improves PDE5 response more than maximal dosing while glucose remains uncontrolled.

Peripheral artery disease and ED coexist; claudication limits activity including sexual exertion. Revascularization decisions precede PDE5 optimization when walking tolerance is the limiting factor for any exertion.

Atrial fibrillation on anticoagulation is not a contraindication to PDE5 use when cardiovascular stability permits sexual activity; bleeding risk from minor trauma is not materially changed by PDE5 vasodilation at approved doses.

Card note: stroke survivors with preserved sexual desire need individualized neurologic assessment; autonomic neuropathy may limit response even when carotid disease is managed. PDE5 trials remain reasonable when partner and mobility context supports safe activity.

Chronic obstructive pulmonary disease and ED overlap through systemic inflammation and hypoxia; optimizing COPD therapy may improve exertional capacity for intercourse before blaming PDE5 failure.

Choosing Among Sildenafil, Tadalafil, and Vardenafil

Head-to-head meta-analyses at equipotent doses show similar odds of successful intercourse across class members. Selection is therefore about pharmacokinetics, side effects, food timing, comorbid indications, and patient preference-not mythical potency rankings.

Card note: choose sildenafil when cost-sensitive PRN use dominates, the patient can plan one hour fasted before activity, and familiarity with the longest post-marketing track record matters. Generic competition makes sildenafil the usual formulary default. Counsel explicitly about high-fat meals delaying onset.

Choose tadalafil when the patient wants a long window (weekend dosing perception), prefers daily low-dose for frequent intercourse or concurrent BPH-LUTS, or cannot reliably separate dosing from meals. Daily 5 mg requires separate prescribing intent from PRN 20 mg; do not conflate strengths.

Choose vardenafil when historical tolerance was good on that molecule, formulary availability exists, or patient preference follows prior experience. PK and food interactions resemble sildenafil more than tadalafil. Strong CYP3A4 inhibitors are contraindicated per label-verify interaction tables.

Switch molecules after adequate trials-not single doses. Guideline-concordant practice tries optimized dose on multiple attempts with correct timing and stimulation before declaring oral therapy failed. Inadequate response to sildenafil 100 mg PRN warrants tadalafil trial, not immediate prosthesis.

Age over 65, hepatic impairment, severe renal impairment, and concomitant CYP3A4 inhibitors push starting doses down per individual labels. Polypharmacy in older men increases orthostatic risk.

Partner timing and alcohol remain non-drug factors. None of the three agents overrides heavy ethanol impairment of performance.

See our monographs for molecule-specific PK tables, interaction lists, and trial citations: sildenafil (PMX-001), tadalafil (PMX-002), vardenafil (PMX-003). Generic equivalence considerations are covered in the companion topic on PDE5 generic substitution.

Card note: insurance step therapy may mandate generic sildenafil trials before approving tadalafil daily-that is economics, not pharmacology. Appeal documentation should cite failed adequate sildenafil trials with correct timing and dose, not mechanism arguments alone.

Men who need both BPH alpha-blocker and ED therapy often land on tadalafil daily for dual indication when labels align; verify blood pressure after initiation regardless of agent.

Re-trial after long gap: vascular status may have changed; previous failure at 50 mg sildenafil before statin initiation may succeed after risk factor control-reassess before labeling patient PDE5-refractory.

Vacuum erection devices combined with PDE5 show additive benefit in some post-prostatectomy protocols-mechanisms differ, timing of device use relative to dose requires urology protocol guidance.

Cost and half-life drive real-world adherence: daily tadalafil suits men with frequent activity; PRN sildenafil suits occasional activity with meal planning tolerance. Patient preference after informed comparison beats prescriber habit.

Headache and flushing at first dose often improve with repeat use or dose reduction-switching molecules for mild vasodilator symptoms is reasonable before declaring class intolerance.

Partner education reduces performance pressure that antagonizes sympathetic tone during attempts; a five-minute conversation sometimes outperforms dose escalation from 50 mg to 100 mg sildenafil.

Men who prefer spontaneity within a long window often choose tadalafil PRN; men who want lowest cost per tablet and predictable short action often accept sildenafil with meal planning-neither choice implies superior pharmacology, only lifestyle fit.

Stimulation first, then pick a card

Erectile dysfunction reflects failure of corporal hemodynamics-arterial inflow, smooth muscle relaxation, and veno-occlusive trapping-during sexual stimulation. Organic disease often shares endothelial pathways with systemic atherosclerosis.

Normal erection requires nitric oxide release activating soluble guanylate cyclase to produce cGMP. PDE5 terminates the signal; oral PDE5 inhibitors prolong cGMP only when arousal already raised NO- they do not generate spontaneous erections.

Sildenafil, tadalafil, and vardenafil share class contraindications with nitrates and riociguat and share vasodilatory adverse effects while differing in half-life, food interactions, and dosing regimens.

Card note: comorbid vascular risk management improves outcomes as much as pill selection. Cardiovascular screening before prescribing mirrors exercise tolerance logic for sexual activity safety.

Agent choice follows pharmacokinetic fit and patient lifestyle, not invented potency hierarchies. Adequate dose trials with correct timing precede second-line therapies. Generic AB-rated products deliver equivalent active moiety pharmacology when sourced from licensed U.S. pharmacies.

AUA and ISSM guidelines anchor lifestyle and comorbidity optimization before pharmacotherapy; PDE5 inhibitors remain first-line oral agents when not contraindicated. Princeton Consensus updates frame exercise capacity assessment for men with known coronary disease contemplating sexual activity.

Integrated care addressing vascular risk, psychology, and pharmacology outperforms PDE5 monotherapy in mixed etiology ED. Second-line intracavernosal alprostadil bypasses the NO requirement locally when oral class fails after optimized trials.

Card note: document IIEF or patient goal at baseline and after eight weeks at optimized dose-objective tracking prevents premature abandonment of effective pharmacotherapy or endless dose escalation without review.

Link to the PDE5 generic equivalence article when patients worry that cost-saving generics changed their outcome-mechanism and counseling constants are the same across AB-rated products from licensed pharmacies.

When oral therapy fails after optimized trials, document dose, attempts, comorbidities, and partner context before referral for injection therapy or prosthesis-future readers of the chart should see pharmacologic reasoning, not "PDE5 didn't work" without detail.

Morning erections that persist despite situational ED support neurologic and vascular capacity; PDE5 inhibitors target the same pathways those nocturnal events use-expect better response when psychogenic barriers are addressed concurrently.

Card note: priapism risk is low at labeled doses but real-educate patients on four-hour rule and emergency presentation. The risk profile is class-wide for sildenafil, tadalafil, and vardenafil at approved ED dosing.

Read the sildenafil, tadalafil, and vardenafil monographs on this site for label-exact dose adjustment tables and registration trial citations that complement this pathway overview.

Card note: erectile function improvement without libido improvement suggests relational or hormonal layers still need attention-PDE5 inhibitors are not aphrodisiacs and do not treat hypoactive desire without separate evaluation.